Business Wire

Kioxia’s AI Project Wins 2020 Field Innovation Award Silver Prize From Japanese Society for Artificial Intelligence

22.6.2021 11:57:00 EEST | Business Wire | Press release

Share

Kioxia Corporation, a world leader in memory solutions, announced today that it was awarded the 2020 Field Innovation Award Silver Prize by the Japanese Society for Artificial Intelligence (JSAI) for its TEZUKA 2020 project. TEZUKA 2020 brought AI and humans together in collaboration to create a new manga, or comic book, in the nearly identical artistic style of manga legend Osamu Tezuka.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210622005554/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Plot development (Graphic: Business Wire)

The Field Innovation Award recognizes individuals and organizations that leverage AI technology to solve real-life issues and advance the state of business and society.

The TEZUKA 2020 project was acclaimed as an innovative use of AI technology to develop a new manga, which involves combining numerous elements of storytelling, including location settings, characters, plot development, dialogues, panel layouts and speech bubbles. Through the AI technology, the project team created prototypes for new plots and characters, all while honoring the unique and highly recognizable Tezuka style. Human artists then used these AI-created prototypes to develop a complete, full-length manga entitled “PHAEDO.”

Kioxia, guided by its mission of uplifting the world with memory, uses AI technology to support creativity as well as to improve production efficiency and quality through memory solutions.

The members of the TEZUKA 2020 project are as follow:

  • Hitoshi Matsubara, Professor at the University of Tokyo
  • Satoshi Kurihara, Professor at Keio University
  • Kazushi Mukaiyama, Professor at Future University Hakodate
  • Yoji Kawano, Assistant Professor at Keio University
  • Atsushi Nakajima, Digital Transformation Technology R&D Center, Kioxia Corporation
  • Atsushi Kunimatsu, SSD Division, Kioxia Corporation
  • Masato Ishiwata, Director of Creative Division, Tezuka Productions
  • Makoto Tezuka, Director at Tezuka Productions
  • Daisuke Tsutsui, Director of Brand & Innovation Division, Wunderman Thompson Tokyo
  • Ryohei Orihara, Digital Transformation Technology R&D Center, Kioxia Corporation

Creating plots with AI
To enable AI to learn the essence of Tezuka’s works and artistry, 130 of his creations were deconstructed and split into 13 common plot development phases to be used as data. The AI technology used that data to generate story outlines (Figure 1), generating over 100 plots in total. Thereafter, the project members discussed the storyline options, some of which had highly unexpected twists that people would not likely have imagined, and ultimately selected the plot that became the basis of “PHAEDO.”

Creating characters with AI
This project used an AI technology called Generative Adversarial Networks (GAN), which learned Tezuka’s authentic artistry to generate characters that were extremely close to his style. Some 4,500 facial images were gathered, but only a small number of the images were ideally suited to machine learning due to their orientation and proportions (Figure 2). To enable the AI to learn the characteristics of Tezuka’s illustrated human faces, the project team introduced a process called “transfer learning” to the AI technology, allowing it to accurately learn Tezuka’s manga characters and generate its own characters in his unique style (Figure 3).

About Kioxia
Kioxia is a world leader in memory solutions, dedicated to the development, production and sale of flash memory and solid-state drives (SSDs). In April 2017, its predecessor Toshiba Memory was spun off from Toshiba Corporation, the company that invented NAND flash memory in 1987. Kioxia is committed to uplifting the world with memory by offering products, services and systems that create choice for customers and memory-based value for society. Kioxia's innovative 3D flash memory technology, BiCS FLASH™, is shaping the future of storage in high-density applications, including advanced smartphones, PCs, SSDs, automotive and data centers.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Kota Yamaji
Public Relations
Kioxia Holdings Corporation
81-3-6478-2319
kioxia-hd-pr@kioxia.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Carnegie Mellon University and Cleveland Clinic Develop AI System to Interpret Cardiac MRI Scans with Enhanced Accuracy21.5.2026 15:05:00 EEST | Press release

A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521762286/en/ A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. The novel system, called CMR-CLIP, is designed to interpret cardiac MRI scans by connecting moving images of the heart with corresponding clinical radio

The Live Moment Effect: Genius Sports and MediaScience Study Finds Specific Moments in Live Sports Can Double Unaided Brand Recall21.5.2026 15:00:00 EEST | Press release

Genius Sports Limited (NYSE: GENI), a global leader in real-time sports data, today released new biometric research conducted with MediaScience showing that ads delivered immediately after emotionally heightened moments in live sports can double unaided brand recall. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521475265/en/ The Live Moment Effect report from Genius Sports and MediaScience. The study, The Live Moment Effect, finds that advertising effectiveness is significantly influenced by a viewer’s emotional state immediately before an ad is shown. In controlled biometric testing, ads shown after high-intensity sporting moments, such as near-scoring plays or crucial momentum shifts, delivered approximately double the unaided brand recall of baseline conditions. The Moment Before the Ad Matters The research challenges long-held assumptions about media value, showing that not all impressions are equal. Live sports rem

Merck Announces First Patient Dosed in Phase 3 Study for Investigational Antibody-Drug Conjugate in Colorectal Cancer21.5.2026 15:00:00 EEST | Press release

Merck, a leading science and technology company, today announced that the first patient has been dosed in the Phase 3 PROCEADE®-CRC-03 trial (NCT07549412). The study is evaluating precemtabart tocentecan (Precem‑TcT), a potential first‑in‑class investigational anti‑CEACAM5 antibody‑drug conjugate (ADC), for the treatment of metastatic colorectal cancer (mCRC). “Leveraging our novel payload‑linker technology, Precem‑TcT is the first CEACAM5‑targeted ADC in clinical studies with an exatecan payload, rationally designed for stability and enhanced cancer cell killing activity,” said David Weinreich, MD, MBA, Global Head of R&D and Chief Medical Officer for the Healthcare business of Merck. “The Phase 3 study and the enrollment of the first patient with Precem-TcT build on the Company’s more than 20 years of expertise in colorectal cancer, and highlight our commitment to advancing differentiated ADCs for heavily pretreated patients with limited treatment options.” The PROCEADE®-CRC-03 study

Baszucki Group Funds Oxford University Clinical Trial of Ketogenic Therapy for Early Psychosis21.5.2026 14:00:00 EEST | Press release

Baszucki Group today announced a £1.17 million grant to support a randomized controlled trial at the University of Oxford assessing the feasibility, safety, and efficacy of a ketogenic diet for patients at clinical high risk of psychosis (CHR-P). Researchers will test this nutritional therapy's ability to improve patients' mental and physical health. This project builds on a growing body of research suggesting the potential of metabolic therapies in treating serious mental illness. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521877110/en/ Baszucki Group Funds £1.17 Million for University of Oxford Trial of Ketogenic Therapy for Early Psychosis Psychotic disorders carry a massive personal burden and are associated with a lower life expectancy. Psychosis does not develop immediately, but typically emerges following a period of early, subtle symptoms. Individuals in this stage, classified as CHR-P, represent a critical pr

SINOVAC Announces Extension of Deadline to Submit Payment Instructions for Previously Declared Special Cash Dividend21.5.2026 13:30:00 EEST | Press release

Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it has extended the deadline for shareholders and nominee brokers to submit payment instructions relating to the Company’s previously declared special cash dividend. The Company previously announced a special cash dividend of US$55.00 per common share, payable to valid holders of the Company’s common shares as of the close of business on May 23, 2025 ET. The Company previously informed shareholders that completed instruction materials were to be submitted prior to December 31, 2025 in order to facilitate receipt of the dividend. The Company has now extended that submission deadline to June 30, 2026. Shareholders and nominee brokers that have not yet submitted their instruction materials are reminded to do so on or before June 30, 2026 in order to facilitate payment of the dividend. If you have any questions regarding the process you need to un

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye